What Is Tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist that activates both incretin receptors simultaneously. Originally developed for type 2 diabetes, clinical studies have shown it may support significant weight management when prescribed alongside diet and exercise.
Unlike single-receptor GLP-1 medications, Tirzepatide’s dual mechanism may provide enhanced appetite management, improved insulin sensitivity, and more significant metabolic improvements. Individual results vary.
How It Works
Tirzepatide works by mimicking two natural hormones: GIP and GLP-1. These hormones are released after eating and play key roles in appetite regulation, insulin production, and glucose metabolism.
- Reduces appetite and food cravings through central nervous system signaling
- Slows gastric emptying, helping you feel full longer after meals
- Improves insulin sensitivity and blood sugar control
- Promotes fat loss while preserving lean muscle mass
- May improve cardiovascular risk factors including blood pressure and cholesterol
What to Expect
Treatment begins with a low dose that gradually increases over several weeks to minimize side effects. Most patients begin noticing reduced appetite within the first 1–2 weeks, with measurable weight loss by week 4–6.
Your physician will monitor your progress through regular check-ins, lab work, and protocol adjustments to ensure optimal results. The medication is administered as a once-weekly subcutaneous injection that can be self-administered at home.
Who Is It For?
Tirzepatide may be appropriate for adults with a BMI of 30 or higher, or a BMI of 27+ with weight-related health considerations. Your physician will evaluate your full health profile during consultation to determine if Tirzepatide may be suitable for you.